FUSN Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.

$2.53
As of 07/01/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  Canada
IPO date:  06/26/2020
Outstanding shares:  43,342,402
Average volume:  19,490
Market cap:   $108,356,005
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BJK0NH0
Valuation   (See tab for details)
PE ratio:   -1.29
PB ratio:   0.50
PS ratio:   53.51
Return on equity:   -38.73%
Net income %:   -4,119.85%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy